4.03
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Revenues |
2.30%
50.53
|
51.72 | 57.22 | 56.26 | 52.59 |
|
|
5.09%
71.84
|
68.36 | - | - | - |
| Costs And Expenses |
12.16%
114.34
|
101.94 | 97.57 | 87.54 | 91.09 |
| Operating Income/Loss |
27.05%
-63.81
|
-50.22 | -40.35 | -31.28 | -38.50 |
| Income/Loss From Continuing Operations Before Tax |
28.83%
-62.38
|
-48.42 | -38.00 | -28.39 | -34.89 |
| Income Tax Expense/Benefit, Deferred |
-
|
- | 103.19 | -5.974 | -7.972 |
| Income Tax Expense/Benefit |
9.79%
0.129
|
0.143 | 103.19 | -5.804 | -7.68 |
| Net Income/Loss |
28.71%
-62.51
|
-48.57 | -141.19 | -22.59 | -27.21 |
| Basic Average Shares |
1.29%
60.23
|
59.46 | 0.0569 | 59.09 | 58.99 |
| Diluted Average Shares |
1.29%
60.23
|
59.46 | 0.0569 | 59.09 | 58.99 |
| Basic Earnings Per Share |
26.83%
-1.04
|
-0.82 | -2.39 | -0.38 | -0.46 |
| Diluted Earnings Per Share |
26.83%
-1.04
|
-0.82 | -2.39 | -0.38 | -0.46 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):